|
New computational technique can predict drug side effects
December 12, 2007Early identification of adverse effects of drugs before they are tested in humans is crucial in developing new therapeutics, as unexpected effects account for a third of all drug failures during the development process. Now researchers at the University of California, San Diego (UCSD) have developed a novel technique using computer modeling to identify potential side effects of pharmaceuticals, and have used the technique to study a class of drugs that includes tamoxifen, the most prescribed drug in the treatment of breast cancer. Their study is currently available on line at PLoS Computational Biology.
Conventional test methods screen compounds in animal studies in advance of human trials in the hope of identifying the side effects of promising therapeutics. The UCSD team - led by Philip Bourne, Ph.D., professor of pharmacology at UCSD's Skaggs School of Pharmacy and Pharmaceutical Sciences and Lei Xie, Ph.D., of the San Diego Supercomputer Center at UCSD - instead uses the power of computational modeling to screen specific drug molecules using a worldwide repository, the Protein Data Bank (PDB), containing tens of thousands of three-dimensional protein structures.
Drug molecules are designed to bind to targeted proteins in order to achieve a therapeutic affect, but if the small drug molecule that functions as a "key" attaches to an off-target protein that has a similar binding site, or "lock," side effects can result.
To identify which proteins might be unintended targets, the UCSD researchers take a single drug molecule and look for how it might bind to as many of the proteins encoded by the human proteome as possible. In this published case study, they looked at Select Estrogen Receptor Modulators (SERMs), a class of drug that includes tamoxifen, to illustrate the novel approach.
"The computer procedure we developed starts with an existing three-dimensional model of a pharmaceutical, showing the structure of a drug molecule bound to its target protein; in this case, the SERM bound to the estrogen receptor," said Bourne, who is co-director of the PDB. The scientists then use computer analysis to search for other binding sites that match that drug binding site - like looking for other locks that can be opened by the same key.
In this study, the team found a previously unidentified protein target for SERMs. The identification of this secondary binding site explains known adverse effects, and opens the door to modifying the drug in a way that maintains binding to the intended target, but reduces binding to the second site.
"If a drug has adverse side effects, it is likely that drug is also binding to an unintended, secondary molecule; in other words, the key that allows it to attach to its target fits more than one lock," said Bourne. He explained that using this computational technique to find another "lock" could result in one of three things: the new lock might show no effect; the lock could explain an adverse side effect of the drug; or the research could potentially discover a new therapeutic effect for an existing drug - drug repositioning.
The UCSD researchers are continuing their studies, which Bourne says can be applied to any drug on the market for which a structure of the drug bound to the receptor exists in the PDB. Bourne emphasized that results from this approach still needed to be tested experimentally.
University of California - San Diego
To identify which proteins might be unintended targets, the UCSD researchers take a single drug molecule and look for how it might bind to as many of the proteins encoded by the human proteome as possible. In this published case study, they looked at Select Estrogen Receptor Modulators (SERMs), a class of drug that includes tamoxifen, to illustrate the novel approach.
"The computer procedure we developed starts with an existing three-dimensional model of a pharmaceutical, showing the structure of a drug molecule bound to its target protein; in this case, the SERM bound to the estrogen receptor," said Bourne, who is co-director of the PDB. The scientists then use computer analysis to search for other binding sites that match that drug binding site - like looking for other locks that can be opened by the same key.
In this study, the team found a previously unidentified protein target for SERMs. The identification of this secondary binding site explains known adverse effects, and opens the door to modifying the drug in a way that maintains binding to the intended target, but reduces binding to the second site.
"If a drug has adverse side effects, it is likely that drug is also binding to an unintended, secondary molecule; in other words, the key that allows it to attach to its target fits more than one lock," said Bourne. He explained that using this computational technique to find another "lock" could result in one of three things: the new lock might show no effect; the lock could explain an adverse side effect of the drug; or the research could potentially discover a new therapeutic effect for an existing drug - drug repositioning.
The UCSD researchers are continuing their studies, which Bourne says can be applied to any drug on the market for which a structure of the drug bound to the receptor exists in the PDB. Bourne emphasized that results from this approach still needed to be tested experimentally.
University of California - San Diego
Drug Side Effects News and Current Drug Side Effects Events RSSMeditation Impacts Blood Pressure, Study Shows
Transcendental Meditation is an effective treatment for controlling high blood pressure with the added benefit of bypassing possible side effects and hazards of anti-hypertension drugs.
Discovery could help stop malaria at its source -- the mosquito
As summer temperatures cool in the United States, fewer mosquitoes whir around our tiki torches. But mosquitoes swarming around nearly 40 percent of the world's population will continue to spread a deadly parasitic disease - malaria.
Community Oncology Explores Pitched Debate Over Anemia-Fighting Drugs
The June issue of Elsevier's Community Oncology takes an in-depth look at the charge that ESAs, generally considered vital to cancer patients' quality of life, are overprescribed for profit.
St. Jude shows gene test not needed if cancer drug given in low doses
Investigators at St. Jude Children's Research Hospital have shown that when the cancer drug irinotecan is given in low doses for multiple days, it eliminates the need to delay treatment to perform costly genetic testing that determines if the patient is at risk for serious treatment side effects, such as neutropenia.
International HIV/AIDS trial finds risks increase on episodic antiretroviral therapy
Results from one of the largest HIV/AIDS treatment trials ever conducted show that a specific strategy of interrupting antiretroviral therapy more than doubles the risk of AIDS or death from any cause.
New sleep medication shows less potential to foster abuse and dependence
As part of the effort to develop effective behavioral and medical sleep therapies, scientists consider the potential for dependence and abuse associated with prescription sleep drugs.
International HIV/AIDS trial finds continuous antiretroviral therapy superior to episodic therapy
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), today announced that enrollment into a large international HIV/AIDS trial comparing continuous antiretroviral therapy with episodic drug treatment guided by levels of CD4+ cells has been stopped.
Cancer drug hope for people with lupus
A drug used to treat cancer may also benefit people with lupus who have complications of the central nervous system. Rheumatologists at the Annual European Congress of Rheumatology in Vienna, Austria heard today (Thursday 9 June) that rituximab is the first drug in a quarter of a century that is making a real impact, and an alternative to previous standard treatments of high-dose steroids, and chemotherapy.
Suspected fatal side effects of drugs in children have risen over past decade
The number of suspected fatal side effects from drugs prescribed to children and reported to the UK’s drugs early warning system, has risen over the past decade, shows research in the Archives of Disease in Childhood.
Serious setback in the long-term treatment of HIV infection
Structured therapeutic interruptions (STI), long hailed as a way of reducing the side effects of long-term AIDS treatment, has been shown to be ineffective, according to a collaborative study between Swiss and British researchers. Professor Rodney Phillips and colleagues at Oxford University's Peter Medawar Building for Pathogen Research and the Zoology Department collaborated with a Swiss Consortium based in Geneva to study the effect of manipulation of the treatment given to Swiss and Spanish nationals infected with HIV. The researchers sought evidence for benefit to patients when potent antiretroviral therapy (ART), the standard treatment of people infected with HIV, is interrupted in a
More Drug Side Effects News Articles
| © 2008 BrightSurf.com |